PCR53 Patient Experiences Before and After Enfortumab Vedotin Neoadjuvant Treatment in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Abstract

Authors

T Flaig Z Hepp S Narayanan J Whyte N Johnson T Matsuda C Hoimes

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×